Nemocnica Poprad a.s.
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses at Nemocnica Poprad a.s.
Clinical research in this area focuses on serious bacterial infections, especially complicated urinary tract infection and acute pyelonephritis. The studies are designed to assess whether new oral treatment options can match or improve upon established hospital therapies, with the goal of supporting effective infection control and better patient recovery.
- Testing a new oral antibiotic approach for hospitalized adults with cUTI and AP
- Comparing treatment effectiveness against standard intravenous care
- Evaluating overall clinical and microbiological response in difficult-to-treat infections
Work at the Poprad site adds to broader efforts to improve practical treatment choices for complex infections.
Cardiovascular Diseases
This research portfolio includes studies in heart failure and broader atherosclerotic cardiovascular disease. The trials aim to understand whether new therapies can reduce major heart and vascular events, ease the burden of heart failure, and improve outcomes for people living with high cardiovascular risk or obesity-related complications.
- Investigating treatment options for heart failure with preserved or mildly reduced ejection fraction and obesity
- Assessing strategies to lower the risk of heart attack, stroke, and other serious vascular events
- Supporting better prevention and long-term management of cardiovascular disease
These studies reflect a strong focus on improving both symptom control and event prevention in cardiovascular care.
Eye Diseases
Clinical trials in ophthalmology at this site address vision-threatening conditions such as diabetic macular edema and wet age-related macular degeneration. The main purpose is to evaluate whether new eye treatments can preserve or improve visual acuity while offering effective alternatives to existing therapies.
- Studying treatments for DME to compare vision outcomes with current standards
- Testing new approaches for wet age-related macular degeneration
- Focusing on better control of retinal disease and protection of sight
At Nemocnica Poprad a.s., this work supports ongoing advances in retinal disease management and vision preservation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Eyepoint Inc.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eyepoint Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnica Poprad a.s.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 to Aflibercept in Participants with Diabetic Macular Edema | Eyepoint Inc. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 3 | Unknown | 2025-06-05 | 2026-05-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.